PMID- 32053103
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20200716
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 58
IP  - 4
DP  - 2020 Apr
TI  - Active pharmacovigilance program in patients affected by psoriasis and 
      inflammatory bowel diseases
.
PG  - 208-213
LID - 10.5414/CP203628 [doi]
AB  - OBJECTIVE: To help identify adverse events (AEs) in new biologic therapies and to 
      spread the culture of pharmaceutical surveillance among patients affected by 
      psoriasis or inflammatory bowel disease (IBD). MATERIALS AND METHODS: This active 
      pharmacovigilance program provided all patients with telephone follow-ups (FU), 
      carried out by a clinical pharmacologist for a total duration of 1 year. 
      Collected AEs were classified according to the MedDRA dictionary. RESULTS: 21 
      patients with psoriasis and 10 patients with IBD were enrolled. In our sample, 
      the AEs reported were frequent but mild, underlining the crucial role of active 
      pharmacovigilance in detecting minor AEs rarely spontaneously reported by the 
      patients. CONCLUSION: According to our experience, a multidisciplinary team is 
      recommended to manage complex therapies improving AE reporting and promoting 
      greater therapeutic adherence.
FAU - Vergani, Hayley M
AU  - Vergani HM
FAU - Calvini, Giulia
AU  - Calvini G
FAU - Mangini, Gloria
AU  - Mangini G
FAU - Mattioli, Francesca
AU  - Mattioli F
FAU - Parodi, Aurora
AU  - Parodi A
FAU - Burlando, Martina
AU  - Burlando M
FAU - Bodini, Giorgia
AU  - Bodini G
FAU - Martelli, Antonietta
AU  - Martelli A
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
SB  - IM
MH  - *Adverse Drug Reaction Reporting Systems
MH  - Biological Therapy/*adverse effects
MH  - Humans
MH  - Inflammatory Bowel Diseases/*drug therapy
MH  - *Pharmacovigilance
MH  - Psoriasis/*drug therapy
EDAT- 2020/02/14 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/02/14 06:00
PHST- 2020/03/18 00:00 [accepted]
PHST- 2020/02/14 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
PHST- 2020/02/14 06:00 [entrez]
AID - 186229 [pii]
AID - 10.5414/CP203628 [doi]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 2020 Apr;58(4):208-213. doi: 10.5414/CP203628.